Status:
UNKNOWN
Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Hyperglucagonemia
Hyperglycemia
Eligibility:
All Genders
18-60 years
Brief Summary
In order to evaluate the potential role of the gastrointestinal (GI) tract in the postprandial hyperglucagonemia, which characterizes type 1 diabetes mellitus (T1DM) (as well as type 2 diabetes mellit...
Eligibility Criteria
Inclusion
- Caucasian over 18 years with T1DM (diagnosed according to WHO's criteria) treated with long-acting insulin
- No residual beta-cell function (arginine test without increment in plasma C-peptide - see below)
- BMI \<30 kg/m2
- Normal haemoglobin
- Informed consent
Exclusion
- Residual beta-cell function (increment in plasma C-peptide during arginine test - see below)
- Known liver disease or affected liver enzymes (ALAT/ASAT \> 2 x upper normal limit)
- Diabetic nephropathy (se-creatinin \> 130 µM and/or albuminuria)
- Proliferative diabetic retinopathy (anamnestic)
- Treatment with medication that cannot be discontinued for 14 hours
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00704795
Start Date
June 1 2008
End Date
October 1 2009
Last Update
June 26 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gentofte University Hospital
Hellerup, Hellerup, Denmark, 2900